Compare stocks

Xlife Sciences AG is a Swiss-based company focused on developing and advancing healthcare and life sciences technologies. It operates primarily in the biotechnology and medical technology sectors, concentrating on early-stage life science projects with significant potential in pharmaceuticals, medical devices, diagnostics, and digital health solutions. The company collaborates with research institutions and industry experts to foster innovation and accelerate the commercialization of health-related technologies. Headquartered in Zurich, Switzerland, Xlife Sciences leverages a strategic geographic location to engage with European research hubs and industry partners. The company's unique approach involves investing in and nurturing a diverse portfolio of projects to diversify risk and maximize value creation.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.